Click here to read the complete article.
Abstract Title:Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori感染：一项随机，双盲，安慰剂对照试验。
摘要来源：
螺旋杆菌。 2023年8月23日：E13017。 EPUB 2023 8月23日。PMID： 37614081 Muhammad Nawawi，Deborah Chew Chia Hsin，Kok Wei Hao，Nik Ritza Kosai Nik Mahmood，Gary Lee Chong Chong Chearn，Zhiqin Wong，Azmi Mohd Tamil，Hazel Joseph，Hazel Joseph，Hazel Joja Affendi affendi affendii affendi affendi affendi affendi affendi affendi raja ali iSM
pribst
背景： 尽管有多种治疗方案，但幽门螺杆菌根除率的下降却带来了重大挑战去医学界。在辅助治疗中添加乳酸杆菌益生菌作为辅助治疗表现出了一些令人鼓舞的结果。 This study aims to investigate the efficacy of Lactobacillus reuteri DSM 17648 in H. pylori eradication and its effect in ameliorating gastrointestinal symptoms and adverse treatment effects.
MATERIALS AND METHODS: This randomized, double-blinded, placebo-controlled trial involved治疗无幽门螺杆菌阳性患者。在接受益生菌或安慰剂4周之前，有90名患者接受了标准的三重治疗2周。 The posttreatment eradication rate was assessed via aC urea breath test in Week 8. The Gastrointestinal Symptom Rating Scale (GSRS) questionnaire and an interview on treatment adverse effects were conducted during this study.
RESULTS: The eradication rate was higher in the probiotic group than in the placebo组，意图分析差异为22.2％（91.1％vs. 68.9％; P = 0.007）和每项协议分析的差异为24.3％（93.2％vs. 68.9％； P = 0.007）。该益生菌组显示出显着到治疗后的降低，便秘，腹痛和总GSRS评分。益生菌组的GSRS得分降低明显高于安慰剂组：消化不良（4.34±5.00 vs. 1.78±5.64; P = 0.026），腹痛（2.64±2.88 vs. 0.89±3.11; p = 0.007; p = 0.007），contipatipation（2.34±3.91 vss）; p = 0.64±3.91 vss；总分数（12.41±12.19 vs. 4.24±13.72; p = 0.004）。益生菌组报告的不良头痛明显减少（0％vs. 15.6％； p = 0.012）和腹痛（0％vs. 13.3％vs.13.3％; P = 0.026）效应。
结论： span and span and and and and and and and and and and and and pyliation h. pylori and h. pylori and h. pyl arteri and h. pyl arteri。 R. Reuteri Wa时的不良治疗效果s作为辅助处理。